{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T12:59:00Z","timestamp":1788699540006,"version":"build-2803163510"},"update-to":[{"DOI":"10.1002\/14651858.cd002003.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,1,20]],"date-time":"2017-01-20T00:00:00Z","timestamp":1484870400000}}],"reference-count":149,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd002003.pub5","type":"journal-article","created":{"date-parts":[[2017,1,20]],"date-time":"2017-01-20T17:13:32Z","timestamp":1484932412000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":114,"title":["Beta-blockers for hypertension"],"prefix":"10.1002","volume":"2017","author":[{"given":"Charles S","family":"Wiysonge","sequence":"first","affiliation":[{"name":"South African Medical Research Council; Cochrane South Africa; Francie van Zijl Drive, Parow Valley Cape Town Western Cape South Africa 7505"},{"name":"Stellenbosch University; Centre for Evidence-based Health Care, Faculty of Medicine and Health Sciences; Cape Town South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazel A","family":"Bradley","sequence":"additional","affiliation":[{"name":"University of the Western Cape; School of Public Health; Private Bag X17 Belville Cape Town South Africa 7535"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy","family":"Volmink","sequence":"additional","affiliation":[{"name":"South African Medical Research Council; Cochrane South Africa; Francie van Zijl Drive, Parow Valley Cape Town Western Cape South Africa 7505"},{"name":"Stellenbosch University; Centre for Evidence-based Health Care, Faculty of Medicine and Health Sciences; Cape Town South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bongani M","family":"Mayosi","sequence":"additional","affiliation":[{"name":"J Floor, Old Groote Schuur Hospital; Department of Medicine; Observatory 7925 Cape Town South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel H","family":"Opie","sequence":"additional","affiliation":[{"name":"Medical School; Hatter Cardiovascular Research Institute; Anzio Road Observatory Cape Town South Africa 7925"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,1,20]]},"reference":[{"key":"10.1002\/14651858.CD002003.pub5-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1001\/jama.285.21.2719","article-title":"Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial","volume":"285","author":"Agodoa","year":"2001","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1053\/j.ajkd.2011.07.018","article-title":"Comparison of measured GFR, serum creatinine, cystatin C, and beta-trace protein to predict ESRD in African Americans with hypertensive CKD","volume":"58","author":"Bhavsar","year":"2011","journal-title":"American Journal of Kidney Disease"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1161\/HYPERTENSIONAHA.111.169367","article-title":"Limitations of analyses based on achieved blood pressure: lessons from the African American study of kidney disease and hypertension trial","volume":"57","author":"Davis","year":"2011","journal-title":"Hypertension"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1053\/j.ajkd.2006.08.004","article-title":"Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial","volume":"48","author":"Norris","year":"2006","journal-title":"American Journal of Kidney Disease"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"issue":"4","key":"10.1002\/14651858.CD002003.pub5-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1016\/S0197-2456(96)00081-5","article-title":"Design and baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study","volume":"17","author":"Wright","year":"1996","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0007|cit7","unstructured":"ASCOT Study Investigators Anglo Scandinavian Cardiac Outcomes Trial. ASCOT-BPLA preliminary results www.ascotstudy.org\/home.htm"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","article-title":"Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial","volume":"366","author":"Dahl\u00f6f","year":"2005","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1097\/HJH.0b013e32834a8a42","article-title":"Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk","volume":"29","author":"Gupta","year":"2011","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1464-5491.2011.03330.x","article-title":"Metabolic syndrome, impaired fasting glucose and obesity, as predictors of incident diabetes in 14 120 hypertensive patients of ASCOT-BPLA: comparison of their relative predictability using a novel approach","volume":"28","author":"Gupta","year":"2011","journal-title":"Diabetic Medicine"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","article-title":"Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial","volume":"361","author":"Server","year":"2003","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD002003.pub5-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1097\/00004872-200106000-00020","article-title":"Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial","volume":"19","author":"Sever","year":"2001","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0014|cit13","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S0140-6736(81)92624-6","article-title":"Beta-blockers or diuretics in hypertension? A six year follow-up of blood pressure and metabolic side effects","volume":"1","author":"Berglund","year":"1981","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0013|cit14","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.0954-6820.1986.tb02790.x","article-title":"Low-dose antihypertensive treatment with a thiazide diuretic is not diabetogenic. A 10-year controlled trial with bendroflumethiazide","volume":"220","author":"Berglund","year":"1986","journal-title":"Acta Medica Scandinavica"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1136\/bmj.293.6555.1145","article-title":"Randomised trial of treatment of hypertension in elderly patients in primary care","volume":"293","author":"Coope","year":"1986","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1161\/01.CIR.0000039288.86470.DD","article-title":"Calcium antagonist Lacidipine slows down progression of asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial","volume":"106","author":"Zanchett","year":"2002","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0018|cit17","first-page":"30","article-title":"Prevalence of carotid atherosclerosis in hypertension: preliminary baseline data from the European Lacidipine Study on Atherosclerosis (ELSA)","volume":"4","author":"Zanchetti","year":"1996","journal-title":"Blood Pressure Supplement"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0017|cit18","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1097\/00004872-199816070-00008","article-title":"Risk factors associated with alterations in carotid intima-media thickness in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis","volume":"16","author":"Zanchetti","year":"1998","journal-title":"Journal of Hypertension"},{"issue":"5","key":"10.1002\/14651858.CD002003.pub5-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00004872-198710000-00009","article-title":"Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial","volume":"5","author":"Wilhelmsen","year":"1987","journal-title":"Journal of Hypertension"},{"issue":"1","key":"10.1002\/14651858.CD002003.pub5-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/0091-7435(81)90004-9","article-title":"Beta-blockers versus saluretics in hypertension. Comparison of total mortality, myocardial infarction, and sudden death: study design and early results on blood pressure reduction","volume":"10","author":"Wilhelmsen","year":"1981","journal-title":"Preventive Medicine"},{"issue":"5","key":"10.1002\/14651858.CD002003.pub5-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1161\/01.HYP.0000143851.23721.26","article-title":"Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study","volume":"44","author":"Bakris","year":"2004","journal-title":"Hypertension"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1001\/jama.290.21.2805","article-title":"A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial","volume":"290","author":"Pepine","year":"2003","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0735-1097(98)00423-9","article-title":"Rationale and design of the International Verapamil SR\/Trandolapril (INVEST)","volume":"32","author":"Pepine","year":"1998","journal-title":"Journal of the American College of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD002003.pub5-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/00004872-198508000-00011","article-title":"Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH)","volume":"3","author":"The IPPPSH Collaborative Group","year":"1985","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/BF00549583","article-title":"The International Prospective Primary Prevention Study in Hypertension (IPPPSH): objectives and methods","volume":"27","author":"The IPPPSH Collaborative Group","year":"1984","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"7 Pt 1","key":"10.1002\/14651858.CD002003.pub5-BIB0026|cit26","first-page":"705","article-title":"The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group","volume":"10","author":"Dahlof","year":"1997","journal-title":"American Journal of Hypertension"},{"issue":"6","key":"10.1002\/14651858.CD002003.pub5-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1161\/01.HYP.32.6.989","article-title":"Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension","volume":"32","author":"Dahlof","year":"1998","journal-title":"Hypertension"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahlof","year":"2002","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S0140-6736(02)08090-X","article-title":"Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Lindhom","year":"2002","journal-title":"Lancet"},{"issue":"No 1 Pt 2","key":"10.1002\/14651858.CD002003.pub5-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/0002-8703(88)90650-3","article-title":"The Medical Research Council Hypertension Trial: the smoking patient","volume":"115","author":"Dollery","year":"1988","journal-title":"American Heart Journal"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD002003.pub5-BIB0031|cit31","first-page":"S75","article-title":"An update on the Medical Research Council Trial","volume":"5","author":"Dollery","year":"1987","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0034|cit32","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1136\/bmj.291.6488.97","article-title":"MRC trial of treatment of mild hypertension: principal results","volume":"291","author":"Medical Research Council Working Party","year":"1985","journal-title":"British Medical Journal"},{"issue":"3","key":"10.1002\/14651858.CD002003.pub5-BIB0032|cit33","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/hrt.59.3.364","article-title":"Coronary heart disease in the Medical Research Council trial of treatment of mild hypertension","volume":"59","author":"Medical Research Council Working Party on Mild Hypertension","year":"1988","journal-title":"British Heart Journal"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0033|cit34","first-page":"539","article-title":"Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension","volume":"ii","author":"Medical Research Council Working Party on Mild to Moderate Hypertension","year":"1981","journal-title":"Lancet"},{"issue":"7","key":"10.1002\/14651858.CD002003.pub5-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1001\/archinte.1991.00400070161023","article-title":"A randomized, placebo- controlled trial of a nutritional-hygienic regimen along with various drug monotherapies.","volume":"151","author":"The Treatment of Mild Hypertension Study Group","year":"1991","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.304.6824.405","article-title":"Medical Research Council trial of treatment of hypertension in older adults: principal results","volume":"304","author":"MRC Working Party","year":"1992","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/bmj.317.7160.713","article-title":"Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"UK Prospective Diabetes Study Group","year":"1998","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPRDS 38","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1001\/jama.1982.03330160044023","article-title":"Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. I. Results of short-term titration with emphasis on racial difference in response","volume":"248","author":"Veterans Administration Cooperative Study Group on Antihypertensive Agents","year":"1982","journal-title":"JAMA"},{"issue":"16","key":"10.1002\/14651858.CD002003.pub5-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1001\/jama.1982.03330160052024","article-title":"Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. II. Results of long-term therapy","volume":"248","author":"Veterans Administration Cooperative Study Group on Antihypertensive Agents","year":"1982","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","volume":"362","author":"The ACCORD Study Group","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1475-2840-7-22","article-title":"First-line antihypertensive treatment in patients with pre-diabetes: rationale, design and baseline results of the ADaPT investigation","volume":"7","author":"Zidek","year":"2008","journal-title":"Cardiovascular Diabetology"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/hrt.2004.057703","article-title":"Favourable long term prognosis in stable angina pectoris: an extended follow up of the angina prognosis study in Stockholm (APSIS)","volume":"92","author":"Hjemdahl","year":"2006","journal-title":"Heart"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0140-6736(98)05012-0","article-title":"Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomised trial","volume":"353","author":"Hansson","year":"1999","journal-title":"Lancet"},{"issue":"11","key":"10.1002\/14651858.CD002003.pub5-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1097\/00004872-199011000-00002","article-title":"The Captopril Prevention Project: a prospective intervention trial of angiotensin converting enzyme inhibition in the treatment of hypertension","volume":"8","author":"The CAPP group","year":"1990","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0140-6736(00)04560-8","article-title":"Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial","volume":"357","author":"CAPRICORN Investigators","year":"2001","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.clinthera.2008.01.007","article-title":"Comparison of the effects of doxazosin and atenololon target organ damage in adults with type 2 diabetes mellitus and hypertension in the CARDHIAC study: a 9-month, prospective, randomized, open-label, blinded-evaluation trial","volume":"30","author":"Barrios","year":"2008","journal-title":"Clinical Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD002003.pub5-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1474-4422(08)70263-1","article-title":"Controlling Hypertension and Hypotension Immediately Post-Stroke (CHHIPS): a randomised, placebo-controlled, double-blind pilot trial","volume":"8","author":"Potter","year":"2009","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial","volume":"353","author":"CIBIS-II Investigators","year":"1999","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(03)13800-7","article-title":"Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomised controlled trial","volume":"362","author":"Poole-Wilson","year":"2003","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1001\/jama.289.16.2073","article-title":"Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial","volume":"289","author":"Black","year":"2003","journal-title":"JAMA"},{"issue":"4","key":"10.1002\/14651858.CD002003.pub5-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S0197-2456(98)00013-0","article-title":"Rationale and design for the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) trial","volume":"19","author":"Black","year":"1998","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1291\/hypres.28.331","article-title":"The combination therapy of hypertension to prevent cardiovascular events (COPE) trial: rationale and design","volume":"28","author":"Ogihara","year":"2005","journal-title":"Hypertension Research"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.jacc.2003.11.037","article-title":"Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study","volume":"43","author":"Rouleau","year":"2004","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/j.1751-7176.2010.00341.x","article-title":"Effect of combining extended-release carvedilol and lisinopril in hypertension: results of the COSMOS study","volume":"12","author":"Bakris","year":"2010","journal-title":"Journal of Clinical Hypertension (Greenwich)"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/1470320308096411","article-title":"Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension","volume":"9","author":"Dietz","year":"2008","journal-title":"Journal of the Renin-Angiotensin-Aldosterone System"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1161\/01.STR.24.4.543","article-title":"Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke","volume":"24","author":"The Dutch TIA Trial Study Group","year":"1993","journal-title":"Stroke"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1559-4572.2008.00017.x","article-title":"Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in patients with type 2 diabetes and hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) study","volume":"3","author":"Phillips","year":"2008","journal-title":"Journal of Cardiometabolic Syndrome"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.jacc.2003.12.040","article-title":"Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial","volume":"43","author":"Gattis","year":"2004","journal-title":"Journal of the American College of Cardiology"},{"issue":"2 Pt 1","key":"10.1002\/14651858.CD002003.pub5-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/ajh\/4.2.151","article-title":"Primary prevention of sudden cardiovascular death in hypertensive patients. Mortality results from the MAPHY Study","volume":"4","author":"Olsson","year":"1991","journal-title":"American Journal of Hypertension"},{"issue":"6 Pt 2","key":"10.1002\/14651858.CD002003.pub5-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1161\/01.HYP.13.6.773","article-title":"Decreased coronary heart disease in hypertensive smokers. Mortality results from the MAPHY study","volume":"13","author":"Tuomilehto","year":"1989","journal-title":"Hypertension"},{"issue":"13","key":"10.1002\/14651858.CD002003.pub5-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1001\/jama.1988.03720130040027","article-title":"Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study","volume":"259","author":"Wikstrand","year":"1988","journal-title":"JAMA"},{"issue":"4","key":"10.1002\/14651858.CD002003.pub5-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1161\/01.HYP.17.4.579","article-title":"Metoprolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY Study","volume":"17","author":"Wikstrand","year":"1991","journal-title":"Hypertension"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.cardfail.2011.05.001","article-title":"Comparative long term effects of nebivolol and carvedilol in hypertensive heart failure patients","volume":"17","author":"Marazzi","year":"2011","journal-title":"Journal of Cardiac Failure"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1161\/hc1002.105180","article-title":"Tolerability of beta blocker initiation and titration in the MetoprololCR\/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF)","volume":"105","author":"Gottlieb","year":"2002","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/08038020701561745","article-title":"Antihypertensive efficacy of zofenopril compared with atenolol in patients with mild to moderate hypertension","volume":"2","author":"Nilsson","year":"2007","journal-title":"Blood Pressure Supplement"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(00)02526-5","article-title":"Randomised trial of the effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study","volume":"356","author":"Hansson","year":"2000","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD002003.pub5-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3109\/08037059309077174","article-title":"A prospective intervention trial of calcium antagonist therapy in hypertension","volume":"2","author":"The Nordic Diltiazem Study (NORDIL)","year":"1993","journal-title":"Blood Pressure Supplement"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jacc.2008.09.046","article-title":"Blood pressure response under chronic antihypertensive drug therapy: the role of aortic stiffness in the REASON (Preterax in Regression of Arterial Stiffness in a Controlled Double-Blind) study","volume":"53","author":"Protogerou","year":"2009","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1161\/01.CIR.101.4.378","article-title":"Effects of metoprolol CR inpatients with ischemic and dilated cardiomyopathy: the randomized evaluation of strategies for left ventricular dysfunction pilot study","volume":"101","author":"RESOLVD Investigators","year":"2000","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","article-title":"Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)","volume":"26","author":"Flather","year":"2005","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/00004872-198608000-00019","article-title":"STOP-Hypertension: Swedish Trial in Old Patients with Hypertension","volume":"4","author":"Dahlof","year":"1986","journal-title":"Journal of Hypertension"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD002003.pub5-BIB0074|cit74","first-page":"S607","article-title":"STOP-Hypertension - preliminary communication from the pilot study of the Swedish Trial in Old Patients with Hypertension","volume":"5","author":"Dahlof","year":"1987","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/0140-6736(91)92589-T","article-title":"Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)","volume":"338","author":"Dahlof","year":"1991","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD002003.pub5-BIB0076|cit76","first-page":"S19","article-title":"Antihypertensive efficacy and side effects of three beta-blockers and a diuretic in elderly hypertensives: a report from the STOP-Hypertension study","volume":"11","author":"Ekbom","year":"1993","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1097\/00004872-199210120-00013","article-title":"Antihypertensive efficacy and side-effects of three beta-blockers and a diuretic in elderly hypertensives: a report from the STOP-Hypertension study","volume":"10","author":"Ekbom","year":"1992","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/S0140-6736(99)10327-1","article-title":"Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study","volume":"354","author":"Hansson","year":"1999","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1159\/000107813","article-title":"Atenolol in the secondary prevention after stroke","volume":"5","author":"Eriksson","year":"1995","journal-title":"Cerebrovascular Diseases"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0895-7061(04)00863-5","article-title":"Calcium channel blockade to prevent stroke in hypertension: a meta-analysis of 13 studies with 103,793 subjects","volume":"17","author":"Angeli","year":"2004","journal-title":"American Journal of Hypertension"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/MJT.0b013e31817fd87e","article-title":"Comparative analysis of beta-blockers with other antihypertensive agents on cardiovascular outcomes in hypertensive patients with diabetes mellitus: a systematic review and meta-analysis","volume":"16","author":"Balamuthusamy","year":"2009","journal-title":"American Journal of Therapeutics"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.amjcard.2007.05.057","article-title":"A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus","volume":"100","author":"Bangalore","year":"2007","journal-title":"American Journal of Cardiology"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.jacc.2008.05.057","article-title":"Beta-blockers for primary prevention of heart failure in patients with hypertension insights from a meta-analysis","volume":"52","author":"Bangalore","year":"2008","journal-title":"Journal of the American College of Cardiology"},{"issue":"10","key":"10.1002\/14651858.CD002003.pub5-BIB0085|cit85","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000039.pub3","article-title":"Interventions for deliberately altering blood pressure in acute stroke","author":"Bath","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0086|cit86","article-title":"Combination of results from a series of 2 X 2 tables; control of confounding","volume-title":"Statistical Methods in Cancer Research, Vol 1: the Analysis of Case-control Data","author":"Breslow","year":"1980"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1161\/01.CIR.102.6.677","article-title":"Nebivolol: a third-generation beta-blocker that augments vascular nitric oxide release: endothelial beta(2)-adrenergic receptor-mediated nitric oxide production","volume":"102","author":"Broeders","year":"2000","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/S0140-6736(04)17355-8","article-title":"Atenolol in hypertension: is it a wise choice?","volume":"364","author":"Carlberg","year":"2004","journal-title":"Lancet"},{"issue":"8","key":"10.1002\/14651858.CD002003.pub5-BIB0089|cit89","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003654.pub4","article-title":"Calcium channel blockers versus other classes of drugs for hypertension","author":"Chen","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0140-6736(90)90944-Z","article-title":"Blood pressure, stroke, and coronary heart disease. Part 2","volume":"325","author":"Collins","year":"1990","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1080\/08037050701246386","article-title":"Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future?","volume":"16","author":"Dahl\u00f6f","year":"2007","journal-title":"Blood Pressure Supplement"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1097\/HJH.0b013e328364ca4c","article-title":"2013 practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH\/ESC Task Force for the Management of Arterial Hypertension","volume":"31","author":"ESH\/ESC Task Force for the Management of Arterial Hypertension","year":"2013","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11886-015-0592-x","article-title":"A comparison of vasodilating and non-vasodilating beta-blockers and their effects on cardiometabolic risk","volume":"17","author":"Fergus","year":"2015","journal-title":"Current Cardiology Reports"},{"issue":"10010","key":"10.1002\/14651858.CD002003.pub5-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(15)00128-2","article-title":"Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"386","author":"Forouzanfar","year":"2015","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/jhh.2010.11","article-title":"Efficacy, safety and tolerability of aliskiren, a direct renin inhibitor, in women with hypertension: a pooled analysis of eight studies","volume":"24","author":"Gradman","year":"2010","journal-title":"Journal of Human Hypertension"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jclinepi.2010.07.017","article-title":"GRADE guidelines: 4. Rating the quality of evidence - study limitations (risk of bias)","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0099|cit99","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/j.cjca.2014.03.003","article-title":"Nebivolol: vasodilator properties and evidence for relevance in treatment of cardiovascular disease","volume":"30","author":"Howlett","year":"2014","journal-title":"Canadian Journal of Cardiology"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1161\/HYPERTENSIONAHA.113.00863","article-title":"Recent clinical trials of hypertension management","volume":"62","author":"Jennings","year":"2013","journal-title":"Hypertension"},{"issue":"24","key":"10.1002\/14651858.CD002003.pub5-BIB0103|cit103","first-page":"2413","article-title":"The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure","volume":"157","author":"JNC-6","year":"1997","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1161\/01.CIR.0000066912.58385.DE","article-title":"Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action","volume":"107","author":"Kalinowski","year":"2003","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/11530710-000000000-00000","article-title":"Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release","volume":"70","author":"Kamp","year":"2010","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1503\/cmaj.060110","article-title":"Re-examining the efficacy of [beta]-blockers for the treatment of hypertension: a meta-analysis","volume":"174","author":"Khan","year":"2006","journal-title":"CMAJ"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.cjca.2014.01.006","article-title":"Atenolol vs non-atenolol beta-blockers for the treatment of hypertension: a meta-analysis","volume":"30","author":"Kuyper","year":"2014","journal-title":"Canadian Journal of Cardiology"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.cjca.2014.02.012","article-title":"Beta-blockers in hypertension: studies and meta-analyses over the years","volume":"30","author":"Larochelle","year":"2014","journal-title":"Canadian Journal of Cardiology"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(05)67573-3","article-title":"Should [beta] blockers remain first choice in the treatment of primary hypertension? A meta-analysis","volume":"366","author":"Lindholm","year":"2005","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0110|cit110","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"Mantel","year":"1959","journal-title":"Journal of the National Cancer Institute"},{"issue":"13","key":"10.1002\/14651858.CD002003.pub5-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJM199304013281303","article-title":"Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents","volume":"328","author":"Materson","year":"1993","journal-title":"New England Journal of Medicine"},{"issue":"23","key":"10.1002\/14651858.CD002003.pub5-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1001\/jama.279.23.1903","article-title":"Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review","volume":"279","author":"Messerli","year":"1998","journal-title":"Journal of the American Medical Association"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/S0895-7061(03)01017-3","article-title":"[Beta]-blockers in hypertension - the emperor has no clothes: an open letter to present and prospective drafters of new guidelines for the treatment of hypertension","volume":"16","author":"Messerli","year":"2003","journal-title":"American Journal of Hypertension"},{"issue":"7","key":"10.1002\/14651858.CD002003.pub5-BIB0114|cit114","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0115|cit115","unstructured":"National Institute for Health and Care Excellence (NICE) Hypertension in adults: diagnosis andmanagement. Clinical guideline. Published: 24 August 2011 nice.org.uk\/guidance\/cg127. Available from https:\/\/www.nice.org.uk\/guidance\/cg127\/resources\/hypertension-in-adults-diagnosis-and-management-35109454941637"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0116|cit116","volume-title":"Hypertension: Management in Adults in Primary Care: Pharmacological Update","author":"National Collaborating Centre for Chronic Conditions","year":"2006"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1136\/bmj.315.7121.1544","article-title":"Evidence is needed that beta blockade alone reduces mortality in hypertension","volume":"315","author":"Opie","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0735-1097(01)01728-4","article-title":"Evidence-based evaluation of calcium channel blockers for hypertension: equality of mortality and cardiovascular risk relative to conventional therapy","volume":"39","author":"Opie","year":"2002","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1097\/01.hjh.0000133732.24501.9e","article-title":"Old antihypertensives and new diabetes","volume":"22","author":"Opie","year":"2004","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1001\/jama.2014.336","article-title":"\u03b2-Blocker therapy for patients with hypertension","volume":"311","author":"Opie","year":"2014","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1370\/afm.708","article-title":"Race and ethnicity in trials of antihypertensive therapy to prevent cardiovascular outcomes: a systematic review","volume":"5","author":"Park","year":"2007","journal-title":"Annals of Family Medicine"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s11906-007-0050-2","article-title":"The vasodilatory beta-blockers","volume":"9","author":"Pedersen","year":"2007","journal-title":"Current Hypertension Reports"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1136\/bmj.315.7101.154","article-title":"Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nifedipine and enalapril in antihypertensive treatment: results of the HANE study","volume":"315","author":"Philipp","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.cjca.2013.12.001","article-title":"Contemporary use of beta-blockers: clinical relevance of sub-classification","volume":"30","author":"Poirier","year":"2014","journal-title":"Canadian Journal of Cardiology"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/MBP.0b013e32833c8a64","article-title":"Different patterns of peripheral versus central blood pressure in hypertensive patients treated with \u03b2-blockers either with or without vasodilator properties or with angiotensin receptor blockers","volume":"15","author":"Pol\u00f3nia","year":"2010","journal-title":"Blood Pressure Monitoring"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/jama.1997.03540330061036","article-title":"Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis","volume":"277","author":"Psaty","year":"1997","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD002003.pub5-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1161\/HYPERTENSIONAHA.115.06467","article-title":"Effects of \u03b2-blockers with and without vasodilating properties on central blood pressure: systematic review and meta-analysis of randomized trials in hypertension","volume":"67","author":"Pucci","year":"2016","journal-title":"Hypertension"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1136\/bmj.319.7210.630","article-title":"British Hypertension Society guidelines for hypertension management 1999; summary","volume":"319","author":"Ramsay","year":"1999","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1177\/1060028013519591","article-title":"Beta-blockers: a review of their pharmacological and physiological diversity in hypertension","volume":"48","author":"Ripley","year":"2014","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1751-7176.2011.00454.x","article-title":"Thiazide diuretics and \u03b2-blockers in the treatment of hypertension in diabetes mellitus","volume":"13","author":"Sander","year":"2011","journal-title":"Journal of Clinical Hypertension (Greenwich)"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/archinternmed.2010.427","article-title":"Antihypertensive treatment and development of heart failure in hypertension: a Bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk","volume":"171","author":"Sciarretta","year":"2011","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0132|cit132","first-page":"698","article-title":"An evaluation of the surgical treatment of hypertension","volume":"25","author":"Smithwick","year":"1949","journal-title":"Bulletin of the New York Academy of Medicine"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1097\/00004872-200306000-00002","article-title":"Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003","volume":"21","author":"Staessen","year":"2003","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/HJH.0000000000000447","article-title":"Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs overview and meta-analyses","volume":"33","author":"Thomopoulos","year":"2015","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1161\/01.HYP.0000125726.92964.ab","article-title":"Adverse prognostic significance of new diabetes in treated hypertensive subjects","volume":"43","author":"Verdecchia","year":"2004","journal-title":"Hypertension"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1161\/01.HYP.0000174591.42889.a2","article-title":"Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention","volume":"46","author":"Verdecchia","year":"2005","journal-title":"Hypertension"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.amjhyper.2005.09.009","article-title":"The role of the new beta-blockers in treating cardiovascular disease","volume":"18","author":"Weber","year":"2005","journal-title":"American Journal of Hypertension"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1161\/CIRCULATIONAHA.105.595496","article-title":"Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study","volume":"113","author":"Williams","year":"2006","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0139|cit139","first-page":"351","article-title":"Beta-blockers and the treatment of hypertension: it is time to move on","volume":"18","author":"Wiysonge","year":"2007","journal-title":"Cardiovascular Journal of Africa"},{"issue":"11","key":"10.1002\/14651858.CD002003.pub5-BIB0140|cit140","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007450.pub2","article-title":"Blood pressure lowering efficacy of partial agonist beta blocker monotherapy for primary hypertension","author":"Wong","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD002003.pub5-BIB0141|cit141","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007452.pub2","article-title":"Blood pressure lowering efficacy of nonselective beta-blockers for primary hypertension","author":"Wong","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0142|cit142","first-page":"25","article-title":"Systematic review of anti-hypertensive therapies: does the evidence assist in choosing a first-line drug?","volume":"161","author":"Wright","year":"1999","journal-title":"CMAJ"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0143|cit143","first-page":"188","article-title":"Choosing a first-line drug in the management of elevated blood pressure: what is the evidence? 2: Beta-blockers","volume":"163","author":"Wright","year":"2000","journal-title":"CMAJ"},{"issue":"3","key":"10.1002\/14651858.CD002003.pub5-BIB0144|cit144","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001841.pub2","article-title":"First-line drugs for hypertension","author":"Wright","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1097\/01.hjh.0000170370.41387.1b","article-title":"Evidence-based medicine in hypertension: what type of evidence?","volume":"23","author":"Zanchetti","year":"2005","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1097\/01.hjh.0000249685.58370.28","article-title":"How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis","volume":"24","author":"Bradley","year":"2006","journal-title":"Journal of Hypertension"},{"issue":"1","key":"10.1002\/14651858.CD002003.pub5-BIB0147|cit147","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002003.pub2","article-title":"Beta-blockers for hypertension","author":"Wiysonge","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD002003.pub5-BIB0148|cit148","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002003.pub4","article-title":"Beta-blockers for hypertension","author":"Wiysonge","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD002003.pub5-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1001\/jama.2013.277510","article-title":"\u03b2-Blockers as initial therapy for hypertension","volume":"310","author":"Wiysonge","year":"2013","journal-title":"JAMA"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD002003.pub5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T03:04:11Z","timestamp":1762398251000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD002003.pub5"}},"subtitle":[],"editor":[{"name":"Cochrane Hypertension Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,1,20]]},"references-count":149,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd002003.pub5","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,20]]}}}